Vertex Pharmaceuticals Inc
VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3029% above fair value
$515.02−5.64 (-1.08%)
Close on Nov 20, 2026Market cap $130.54BP/E 30.0Yield –
Vertex Pharmaceuticals Deferred tax assets: $3,011M in Q2 2026, up 11.0% from a year earlier. That is the highest of the 31 quarters on record here.
Latest, Q2 2026
3,011
Period ended Jun 30, 2026
Change on a year earlier
+11.0%
2,712 in Q2 2025
History
31 quarters
Since Q4 2018
Sources
29
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K (DB).
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Deferred tax assets ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 3,011 | +11.0% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2026 | Mar 31, 2026 | 2,948 | +15.9% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 2,898 | +24.3% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2025 | Sep 30, 2025 | 2,937 | +27.2% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 2,712 | +24.1% | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 2,544 | +29.6% | Form 10-Q (filed 2025-05-06) ↗ |
| Q4 2024 | Dec 31, 2024 | 2,331 | +28.6% | Form 10-K (filed 2025-02-13) ↗ |
| Q3 2024 | Sep 30, 2024 | 2,309 | +33.5% | Form 10-Q (filed 2024-11-05) ↗ |
| Q2 2024 | Jun 30, 2024 | 2,186 | +42.1% | Form 10-Q (filed 2024-08-02) ↗ |
| Q1 2024 | Mar 31, 2024 | 1,963 | +44.3% | Form 10-Q (filed 2024-05-07) ↗ |
| Q4 2023 | Dec 31, 2023 | 1,812 | +45.3% | Form 10-K (filed 2024-02-15) ↗ |
| Q3 2023 | Sep 30, 2023 | 1,729 | +48.7% | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2023 | Jun 30, 2023 | 1,538 | +34.5% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2023 | Mar 31, 2023 | 1,360 | +43.8% | Form 10-Q (filed 2023-05-02) ↗ |
| Q4 2022 | Dec 31, 2022 | 1,247 | +33.4% | Form 10-K (filed 2023-02-10) ↗ |
| Q3 2022 | Sep 30, 2022 | 1,163 | +24.5% | Form 10-Q (filed 2022-10-28) ↗ |
| Q2 2022 | Jun 30, 2022 | 1,144 | +20.0% | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2022 | Mar 31, 2022 | 946 | +15.9% | Form 10-Q (filed 2022-05-06) ↗ |
| Q4 2021 | Dec 31, 2021 | 935 | +5.9% | Form 10-K (filed 2022-02-09) ↗ |
| Q3 2021 | Sep 30, 2021 | 934 | -18.6% | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2021 | Jun 30, 2021 | 953 | -21.6% | Form 10-Q (filed 2021-07-30) ↗ |
| Q1 2021 | Mar 31, 2021 | 816 | -28.9% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2020 | Dec 31, 2020 | 883 | -25.9% | Form 10-K (filed 2022-02-09) ↗ |
| Q3 2020 | Sep 30, 2020 | 1,148 | -18.9% | Form 10-Q (filed 2020-10-30) ↗ |
| Q2 2020 | Jun 30, 2020 | 1,215 | -14.7% | Form 10-Q (filed 2020-07-31) ↗ |
| Q1 2020 | Mar 31, 2020 | 1,148 | -21.8% | Form 10-Q (filed 2020-05-01) ↗ |
| Q4 2019 | Dec 31, 2019 | 1,191 | -20.6% | Form 10-K (filed 2020-02-13) ↗ |
| Q3 2019 | Sep 30, 2019 | 1,416 | – | Form 10-Q (filed 2019-10-31) ↗ |
| Q2 2019 | Jun 30, 2019 | 1,425 | – | Form 10-Q (filed 2019-08-01) ↗ |
| Q1 2019 | Mar 31, 2019 | 1,468 | – | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2018 | Dec 31, 2018 | 1,500 | – | Form 10-Q (filed 2019-05-01) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Deferred tax assets ($M), quarterly Q4 2018–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/fs-dta
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.
See a number that looks wrong?